Arcus Biosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Arcus Biosciences, Inc. (RCUS) on November 17, 2021. The filing details a material definitive agreement involving an amendment to the existing Option, License and Collaboration Agreement with Gilead Sciences, Inc., originally dated May 27, 2020.
Key Financial Metrics and Transaction Terms
- Upfront Payment: Upon closing, Gilead will pay Arcus an aggregate of $725 million in option fees for the exercise of options on three specific programs.
- Programs Involved: The anti-TIGIT program (domvanalimab and AB308), the adenosine receptor antagonist program (etrumadenant), and the CD73 program (quemliclustat).
- Cost Sharing: For the three optioned programs, the companies will co-develop and equally share global development costs and all profits and losses for the United States, subject to expense caps and true-up adjustments.
- Commercialization Rights: Gilead obtains exclusive rights to commercialize the optioned programs outside the U.S., subject to existing partner rights.
- Royalties: Gilead will pay Arcus tiered royalties on non-U.S. revenues ranging from the mid-teens to the low twenties.
- Continuation Payment Adjustment: The $100 million option continuation payment originally due in 2022 is waived if all three programs close. If only one or two programs close, the payment is reduced to $67 million or $34 million, respectively.
Material Changes and New Agreements
The primary material change is the exercise of options by Gilead for three Arcus programs, triggering the $725 million payment. Additionally, the parties agreed to collaborate on discovery and early development for two novel research targets. For these new research programs:
- Gilead has the right to exercise an option for $60 million per program upon completion of IND-enabling activities.
- If exercised early, royalties on non-U.S. commercialization range from high single digits to low double digits.
- If exercised later (post-development milestone), royalties range from high-teens to low twenties.
Outlook, Risks, and Contingencies
The transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act. The filing does not provide specific financial guidance, revenue projections, or liquidity metrics beyond the terms of this specific agreement. The full terms of the amendment will be filed as an exhibit to the Annual Report on Form 10-K for the year ending December 31, 2021.
Key Facts for Investor Verification
- Confirmation of the closing date and receipt of the $725 million option fee.
- Status of the Hart-Scott-Rodino Antitrust review.
- Specific expense caps and true-up adjustment mechanisms for U.S. development costs.
- Details regarding the two new research programs and the timeline for IND-enabling activities.
- Impact of the waived or reduced 2022 continuation payment on future cash flow projections.